Baseline TMTV and Dmax prognostic value in patients with advanced melanoma treated with first-line immune checkpoint inhibitors

被引：0
|
作者：
Vercellino, L. [1 ]
Jallerat, P. [1 ]
Delyon, J. [1 ]
Martineau, A. [1 ]
Baroudjian, B. [1 ]
Poudroux, W. [1 ]
Lebbe, C. [1 ]
Merlet, P. [1 ]
机构：
[1] Hop St Louis, Paris, France
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2022年 / 49卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-693
引用
收藏
页码：S231 / S231
页数：1
相关论文
共 50 条
  • [41] Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors
    Asher, Nethanel
    Marom, Edith M.
    Ben-Betzalel, Guy
    Baruch, Erez Nissim
    Steinberg-Silman, Yael
    Schachter, Jacob
    Shapira-Frommer, Ronnie
    Markel, Gal
    ONCOLOGIST, 2019, 24 (05): : 640 - 647
  • [42] Efficacy of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma
    Birsen, Gary
    Gounant, Valerie
    Girard, Nicolas
    Cadranel, Jacques
    Monnet, Isabelle
    Raynaud-Donzel, Christine
    Fabre, Elizabeth
    Leprieur, Etienne Giroux
    Leroy, Karen
    Damotte, Diane
    Alifano, Marco
    Arrondeau, Jennifer
    Creme, Isabelle
    Chapron, Jeanne
    Wislez, Marie
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (09)
  • [43] Predictive biomarkers and mechanistic insights in stage III/IV melanoma patients undergoing first-line immune checkpoint inhibitors therapy
    Figueiredo, Amanda B.
    Evangelista, Guilherme F. B.
    Silva, Milton J. B.
    Kuil, Larissa M.
    Cavalcanti, Clara M.
    Morais, Katia L. P.
    Apostolico, Juliana S.
    Balderas, Robert
    Lopes, Rodrigo P.
    Silva, Israel T.
    Defelicibus, Alexandre
    Valieris, Renan
    Turner, James
    Galdino, Nayane A. L.
    Santos, Iasmim P.
    Ferreira, Stephanie M. I.
    Lopes, Ananda D.
    Pinto, Clovis A. L.
    Chojniak, Rubens
    Duprat-Neto, Joao P.
    Gollob, Kenneth J.
    CANCER IMMUNOLOGY RESEARCH, 2025, 13 (02)
  • [44] Outcome and impact of immune related adverse events in patients with advanced melanoma treated with checkpoint inhibitors
    Angeles, A.
    Wind, K.
    Tong, C.
    Lee, D. G.
    Bernstein, V.
    Metcalf, C.
    Bahl, G.
    Nguyen, T. P.
    Savage, K. J.
    ANNALS OF ONCOLOGY, 2021, 32 : S878 - S878
  • [45] Enhanced dacarbazine efficacy in advanced melanoma patients previously treated with immune checkpoint inhibitors in Korea
    Lee, Soo Jung
    Na, Jihyun
    Lee, In Hee
    Lee, Jeeyeon
    Lee, Seok-Jong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer
    Remon, Jordi
    Besse, Benjamin
    CURRENT OPINION IN ONCOLOGY, 2017, 29 (02) : 97 - 104
  • [47] Prognostic Significance of Hematological Indices in Malignant Melanoma Treated With Immune Checkpoint Inhibitors
    Afzal, Muhammad Z.
    Sarwar, Tayyaba
    Shirai, Keisuke
    JOURNAL OF IMMUNOTHERAPY, 2019, 42 (07) : 251 - 264
  • [48] Nutritional status as prognostic factor of advanced oesophageal cancer patients treated with immune checkpoint inhibitors
    Chen, Ning
    Yu, Ying
    Shen, Wanji
    Xu, Xiaoling
    Fan, Yun
    CLINICAL NUTRITION, 2024, 43 (01) : 142 - 153
  • [49] The prognostic role of "drug score" on the outcome of advanced cancer patients treated with immune checkpoint inhibitors
    Perrone, F.
    Bersanelli, M.
    Cortellini, A.
    Casartelli, C.
    Bordi, P.
    Tiseo, M.
    Buti, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S714 - S715
  • [50] The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors
    Perrone, Fabiana
    Minari, Roberta
    Bersanelli, Melissa
    Bordi, Paola
    Tiseo, Marcello
    Favari, Elda
    Sabato, Roberto
    Buti, Sebastiano
    JOURNAL OF IMMUNOTHERAPY, 2020, 43 (06) : 196 - 203
12345